Dupilumab study for clearing mucus in moderate to severe asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether dupilumab improves how well mucus is cleared from the airways in adults with moderate to severe asthma. It may help find better ways to reduce mucus-related breathing problems in people with a specific asthma type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be over 18 years old
- Have moderate to severe asthma that looks like “type 2” asthma and is not well controlled (Asthma Control Test score under 20)
- Meet specific lung function and breathing test cutoffs (like FEV1 under 90% predicted and FEV1/FVC under 75%)
- Have evidence of “type 2” airway inflammation from blood and breath markers (eosinils over 300, and FeNO over 25)
- Have needed medium-to-high dose inhaled steroid treatment for asthma (at least fluticasone-equivalent 500 mcg/day)
- Not have used dupilumab before, and avoid certain asthma medicines like anti–IL-5 drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to monitor severe asthma that is driven by high levels of inflammation (T2-high). It involves a bronchoscopy (a thin tube to look inside your lungs) to see how well the treatment is working.
This study tests if the medicine Dupilumab can help control asthma and wheezing in children ages 2 to just under 6. It is for children whose symptoms are not well-managed with their current inhaler.
This study looks at how a viral infection affects people with well-controlled asthma. It tests whether specific asthma-related immune signals can predict who reacts more to a virus, which may help guide future asthma care.
This study tests depemokimab, an injectable biologic, to see how it works in the lungs of people with severe asthma. You would get the drug and have special imaging and a bronchoscopy (a tube with a camera placed into your airways to take tiny tissue samples) so doctors can understand how the medicine reduces inflammation.
This trial tests whether dupilumab, a medicine that helps reduce airway inflammation, can help people with asthma achieve remission. You may be eligible if you have asthma with high markers of inflammation and have had asthma attacks despite using your regular inhaler.
This study tests if a drug called dupilumab, given as a shot under the skin, can reduce airway inflammation in people aged 40-85 with moderate-to-severe COPD who also have signs of a specific type of inflammation called Type 2. It may help if you have frequent flare-ups and are already using multiple inhalers.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.